

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **ASCENTAGE PHARMA GROUP INTERNATIONAL**

**亞盛醫藥集團**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6855)**

### **Voluntary Announcement**

#### **Approval for the Phase Ib/II Clinical Study of APG-2575 in China**

Ascentage Pharma Group International (the “**Company**”) is pleased to announce that it has received approval from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for a Phase Ib/II clinical trial in China of APG-2575, a novel Bcl-2 selective inhibitor being developed by the Company.

This open-label, Phase Ib/II dose-escalation and dose-expansion study is designed to evaluate the safety, tolerability, and preliminary anticancer activity of APG-2575 as a single agent or in combination therapies for the treatment of patients with r/r CLL/SLL in China.

APG-2575 is a novel, orally administered Bcl-2 selective inhibitor being developed by the Company. The Phase I trial of APG-2575 in hematological malignancies is ongoing in China, the U.S. and Australia. APG-2575 is also the first China-made Bcl-2 selective inhibitor to enter clinical trials in China.

The Company believes that recent approvals for a series of Phase Ib/II trials in China and the U.S of APG-2575 are based on satisfactory preclinical and early-stage clinical data. The Company will actively carry forward the product’s clinical studies globally, in hope of providing benefits for the patients soon.

**Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** We cannot guarantee that we will be able to obtain further approval for, or ultimately market, APG-2575 successfully.

By order of the Board  
**Ascentage Pharma Group International**  
**Dr. Yang Dajun**  
*Chairman and Executive Director*

Suzhou, People's Republic of China, April 7, 2020

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng, Dr. Tian Yuan, Mr. Zhao Qun, Dr. Lu Simon Dazhong and Mr. Liu Qian as non-executive Directors, and Mr. Ye Changqing, Dr. Yin Zheng and Mr. Ren Wei as independent non-executive Directors.*